Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- US FDA Approves Novel Antipsychotic Agent Rexulti: Otsuka, Lundbeck
July 14, 2015
- Merck Serono Names Former Allergan Japan President Leo Lee as New President
July 14, 2015
- BIKEN to Map Out 5-Year Biz Plan, Eyes Collaboration for PIII: Director
July 13, 2015
- BIKEN to Produce and Ship Same Amount of Seasonal Flu Vaccines as Last Season: Director Yamanishi
July 13, 2015
- Takeda Submits Plans to Improve Business Practices
July 13, 2015
- Generic Share Increases to 52.0% in FY2014: JGA
July 13, 2015
- MTPC Files for Partial Change to Remicade Dosage for Psoriasis
July 13, 2015
- Hisamitsu Starts PII/III Study of Analgesic Transdermal Patch in Japan
July 13, 2015
- “Equal Sense of Gratitude and Responsibility” in Wake of New Generic Share Target of 80%: Nippon Chemiphar President
July 10, 2015
- Lilly Japan, Sumitomo Dainippon to Collaborate in Sales of Once-Weekly GLP-1 Receptor Agonist
July 10, 2015
- AZ Divests Rights to Develop, Sell GI Treatment Entocort Worldwide Excluding US to Tillotts
July 10, 2015
- Anti-PCSK9 Antibody Demonstrates Favorable Results in PIII Study for Japanese Patients: Sanofi, Regeneron
July 10, 2015
- Doctors Desire New Drugs for Dementia in Japan: Survey
July 9, 2015
- AbbVie to Initiate Clinical Study of Antibody-Drug Conjugate ABT-414 for Malignant Glioma in Japan
July 9, 2015
- Ethical Drug Sales Unchanged in May: Crecon Report
July 8, 2015
- Sawai Gearing Up to Revise 3-Year Biz Plan after New Generic Target
July 8, 2015
- Towa to Issue Convertible Bonds with Face Value of 15 Billion Yen
July 8, 2015
- ASCO Immunotherapy Roundup - 1: Opdivo Data Boost Confidence in BMS’s Combination Strategy
July 7, 2015
- Series: ASCO Immunotherapy Roundup
July 7, 2015
- Japan, US, Europe Anti-Infective Agent Markets Grow 48.4% in FY2014 Driven by Anti-HCV Treatments: Survey
July 7, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…